This Intratumoral cancer therapies- Market Insight, Epidemiology and Market Forecast-2032 report delivers an in-depth understanding of the Intratumoral cancer therapies, historical and forecasted epidemiology as well as the Intratumoral cancer therapies trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Intratumoral cancer therapies market report provides emerging drugs, Intratumoral cancer therapies market share of the individual cancer types, current and forecasted Intratumoral cancer therapies market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Intratumoral cancer therapies unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Many cancers are not inflamed (“cold”) and thus, are not recognized by the immune system, intratumoral (IT) approach is one such approach where pharma company trying to turn “cold” tumors to “hot” that shows signs of inflammation so that they can be infiltrated with T cells, working to fight the cancer. These tumors are easier to treat, as immunotherapy drugs can boost up the immune response.
There are different categories of intratumoral therapies: cytokines, pathogen-associated molecular patterns (PAMPs), oncolytic viruses, cancer gene therapy, monoclonal antibodies, and small molecules. Currently, only three intratumoral therapies are approved, namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen) approved in the US, Europe and Japan in 2015, DELYTACT (teserpaturev/G47∆; Daiichi Sankyo) approved in Japan in 2021 and HENSIFY (Nanobiotix) approved in European market in 2019.
In 2021, the total indication wise target patient pool cases across 7MM were about 469 K which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted intratumoral cancer therapies epidemiology [segmented as Total Incident cases of selected cancer types (Melanoma, Nonmelanoma skin cancer, Head and Neck Cancer, Pancreatic Cancer, Breast Cancer, Brain Cancer, and Soft Tissue Sarcoma), Target patient Pool of intratumoral therapies by Cancer Types and Treated cases by Cancer Types] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
This segment gives a thorough detail of intratumoral cancer therapies market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, the intratumoral cancer therapies market in 7MM is expected to witness a major change in the study period 2019-2032.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The Intratumoral cancer therapies market report provides emerging drugs, Intratumoral cancer therapies market share of the individual cancer types, current and forecasted Intratumoral cancer therapies market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Intratumoral cancer therapies unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Intratumoral cancer therapies Understanding and Treatment Algorithm
The publisher's Intratumoral cancer therapies epidemiology report gives a thorough understanding of Intratumoral (IT) cancer therapies by including details such as overview of Intratumoral Cancer Therapies, advantages, disadvantages and available therapies. Comprehensive epidemiology insight of the tumors targeted by Intratumoral Cancer Therapies. IT therapy refers to any therapy that is delivered in very close anatomical proximity to a tumor with the intention of direct uptake by tumors or tumor cells. It is a therapeutic strategy which aims to use the tumor as its own vaccine. Using tumor as a source of antigens expressed across multiple tumor clones, IT immunotherapies aim to initiate local recruitment of immune cells into the tumor microenvironment and subsequently prime T cells for a systemic polyclonal antitumor response (abscopal effect), potentially addressing intra and inter-tumoral heterogeneity.Many cancers are not inflamed (“cold”) and thus, are not recognized by the immune system, intratumoral (IT) approach is one such approach where pharma company trying to turn “cold” tumors to “hot” that shows signs of inflammation so that they can be infiltrated with T cells, working to fight the cancer. These tumors are easier to treat, as immunotherapy drugs can boost up the immune response.
There are different categories of intratumoral therapies: cytokines, pathogen-associated molecular patterns (PAMPs), oncolytic viruses, cancer gene therapy, monoclonal antibodies, and small molecules. Currently, only three intratumoral therapies are approved, namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen) approved in the US, Europe and Japan in 2015, DELYTACT (teserpaturev/G47∆; Daiichi Sankyo) approved in Japan in 2021 and HENSIFY (Nanobiotix) approved in European market in 2019.
Intratumoral Cancer Therapies Epidemiology
The epidemiology section provides the insights about historical and current indication wise eligible patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted intratumoral cancer therapies epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.In 2021, the total indication wise target patient pool cases across 7MM were about 469 K which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted intratumoral cancer therapies epidemiology [segmented as Total Incident cases of selected cancer types (Melanoma, Nonmelanoma skin cancer, Head and Neck Cancer, Pancreatic Cancer, Breast Cancer, Brain Cancer, and Soft Tissue Sarcoma), Target patient Pool of intratumoral therapies by Cancer Types and Treated cases by Cancer Types] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Intratumoral Cancer Therapies Epidemiology
The epidemiology segment also provides the intratumoral cancer therapies epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.Drug Chapters
The drug chapter segment of the intratumoral cancer therapies report encloses the detailed analysis of intratumoral cancer therapies marketed drugs and late stage (Phase III and Phase II) pipeline drugs. It also helps to understand the intratumoral cancer therapies clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.Emerging Drugs
The report provides the details of the emerging intratumoral cancer therapies under the late and mid-stage of development for selected indications treatment.Intratumoral cancer therapies Market Outlook
The Intratumoral cancer therapies market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted intratumoral cancer therapies market trends by analyzing the impact of current therapies on the market, unmet needs, and demand of better technology.This segment gives a thorough detail of intratumoral cancer therapies market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, the intratumoral cancer therapies market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
The intratumoral cancer therapies market size in the 7MM is expected to change during the study period 2019-2032. The intratumoral cancer therapies therapeutic market in the seven major markets is expected to increase during the study period (2019-2032). In 2021, the total market size of intratumoral cancer therapies was approximately USD 93 million which is expected to rise during the study period (2019-2032).The United States Market Outlook
The total market size of intratumoral cancer therapies in the United States accounted for USD 21 million in 2021 which is expected to rise during the study period (2019-2032).EU-5 Countries: Market Outlook
In EU5, the total market size of intratumoral cancer therapies was USD 22 million in 2021, which is expected to rise during the study period (2019-2032).Japan Market Outlook
In Japan, the total market size of intratumoral cancer therapies was USD 0.2 million in 2021, which is expected to rise during the study period (2019-2032).Intratumoral Cancer Therapies Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the intratumoral cancer therapies market or expected to get launched in the market during the study period 2019-2032. The analysis covers intratumoral cancer therapies market uptake by drugs; patient uptake by therapies; and sales of each drug.This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Intratumoral Cancer Therapies Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses key players involved in developing intratumoral cancer therapies.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing patent details, and other information for emerging intratumoral cancer therapies.Reimbursement Scenario in Intratumoral Cancer Therapies
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.KOL-Views
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the intratumoral cancer therapies domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or intratumoral cancer Therapies market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.Competitive Intelligence Analysis
The publisher performs Competitively and Market Intelligence analysis of the intratumoral Cancer Therapies Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.Scope of the Report
- The report covers a detailed overview of the development of intratumoral cancer therapies across the several selected indications, explaining its various classes, benefits, and challenges for future
- Comprehensive insight has been provided into the intratumoral cancer therapies epidemiology and treatment in the 7MM.
- Additionally, an all-inclusive account of both the current and emerging therapies for intratumoral cancer therapies is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of intratumoral cancer therapies market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global intratumoral cancer therapies market.
Report Highlights
- In the coming years, intratumoral cancer therapies market is set to change due to improved patient outcomes, treatment of cold tumors, rich emerging pipeline and convenient production and administration; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence intratumoral cancer therapies R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for intratumoral cancer therapies. Launch of emerging therapies, will significantly impact the intratumoral cancer therapies market.
- This in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Intratumoral Cancer Therapies Report Insights
- Patient Population
- Therapeutic Approaches
- Intratumoral Cancer Therapies Pipeline Analysis
- Intratumoral Cancer Therapies Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Intratumoral Cancer Therapies Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Intratumoral Cancer Therapies Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Intratumoral Cancer Therapies Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
Key Questions Answered
Market Insights:
- What was the intratumoral cancer therapies Market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the intratumoral cancer therapies total market size as well as market size by therapies across the 7MM during the study period (2019-2032)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest intratumoral cancer therapies market size during the study period (2019-2032)?
- At what CAGR, the intratumoral cancer therapies market is expected to grow in the 7MM during the study period (2019-2032)?
- What would be the intratumoral cancer therapies market outlook across the 7MM during the study period (2019-2032)?
- What would be the intratumoral cancer therapies market growth till 2032 and what will be the resultant market size in the year 2032?
- Intratumoral cancer therapies patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
Epidemiology Insights:
- What is the challenges and unmet needs of the intratumoral cancer therapies?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical intratumoral cancer therapies patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
- What would be the forecasted patient pool of intratumoral cancer therapies in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to intratumoral cancer therapies?
- Out of all the 7MM countries, which country would have the highest incident population of intratumoral cancer therapies during the study period (2019-2032)?
- At what CAGR the population is expected to grow by 7MM during the study period (2019-2032)?
- What are the various recent and upcoming events which are expected to improve the uptake of intratumoral cancer therapies?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the marketed intratumoral cancer therapies and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing intratumoral cancer therapies for the treatment of selected cancers?
- How many intratumoral cancer therapies are in-development by each company for selected cancer treatment?
- How many are emerging intratumoral cancer therapies in mid-stage, and late stage of development for selected cancers treatment?
- What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the intratumoral cancer therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for intratumoral cancer therapies and its status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging intratumoral cancer therapies?
- What are the global historical and forecasted markets of intratumoral cancer therapies?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the intratumoral cancer therapies market
- To understand the future market competition in the intratumoral cancer therapies market and Insightful review of the key unmet needs
- Organize sales and marketing efforts by identifying the best opportunities for intratumoral cancer therapies in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the intratumoral cancer therapies market
- To understand the future market competition in the intratumoral cancer therapies market
Table of Contents
1. Key Insights2. Report Introduction4. Key Highlights from Report6. Epidemiology and Market Forecast Flow9. Key Endpoints in Intratumoral Cancer Therapies12. Attribute Analysis15. KOL Views16. SWOT analysis17. Unmet Needs19. Publisher Capabilities20. Disclaimer21. About the Publisher
3. Intratumoral cancer therapies Market Overview at a Glance
5. Executive Summary of Intratumoral cancer therapy
7. Background and Overview
8. Epidemiology and Patient Population
10. Marketed Therapies
11. Emerging Therapies
13. Intratumoral Cancer Therapies: 7 Major Market Analysis
14. Market Access and Reimbursement
18. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Nanobiotix
- Sirnaomics
- Apexigen
- Replimune
- Merck & Co (Viralytics)
- Highlight Therapeutics
- OncoSec Medical Incorporated
- Intensity Therapeutics
- DNAtrix
- Treovir
- Philogen
- Lokon Pharma AB
- Regeneron
- Istari Oncology
- Amgen
- Daiichi Sankyo
